SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001104659-24-030638
Filing Date
2024-03-04
Accepted
2024-03-04 20:07:54
Documents
2
Group Members
ABV SPV I GP LLCAVALON BIOVENTURES GP, LLCAVALON BIOVENTURES I, LPAVALON BIOVENTURES SPV I, L.P.AVALON VENTURES XI GP LLCBRADEN BOHRMANNJAY LICHTER, PH.D.KEVIN KINSELLARICHARD LEVANDOVSANFORD MADIGAN, PH.D.SERGIO DURONTIGHE REARDON

Document Format Files

Seq Description Document Type Size
1 SC 13D/A tm247915d1_sc13da.htm SC 13D/A 233592
2 EXHIBIT 99.A tm247915d1_ex99a.htm EX-99.A 10441
  Complete submission text file 0001104659-24-030638.txt   246040
Mailing Address 1134 KLINE STREET LA JOLLA CA 92037
Business Address 1134 KLINE STREET LA JOLLA CA 92037 8583482180
Avalon Ventures XI, L.P. (Filed by) CIK: 0001652901 (see all company filings)

IRS No.: 474748883 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92596 | Film No.: 24717769
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)